Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

A 560% Profit and an Update on Three Hot Biotech Stocks

When we recommended Celldex Therapeutics Inc. (Nasdaq: CLDX) to you in the April 2012 special research report "The Biotech Buyout Binge," shares of the Needham, Mass.-based oncology firm were trading at $5.19 a share.

Yesterday, Celldex shares hit a new 52-week high of $34.24 - representing a 560% gain in just 17 months.

And Leerink Swann analyst Howard Liang on Monday lifted his Celldex target price from $29 to $45 - which is 767% above where we recommended the stock to you.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK